Oxford Biomedica plc (LON:OXB) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Oxford Biomedica plc (LON:OXB) have been assigned an average rating of “Moderate Buy” from the seven brokerages that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is GBX 687.

OXB has been the subject of several research reports. Stifel Nicolaus reaffirmed a “buy” rating and issued a GBX 950 price target on shares of Oxford Biomedica in a report on Wednesday, March 11th. Jefferies Financial Group initiated coverage on shares of Oxford Biomedica in a report on Monday, March 23rd. They issued a “buy” rating and a GBX 827 price target for the company.

Oxford Biomedica Stock Performance

LON OXB opened at GBX 618 on Monday. Oxford Biomedica has a one year low of GBX 291 and a one year high of GBX 952. The company has a 50-day simple moving average of GBX 606.12 and a 200-day simple moving average of GBX 664.84. The company has a debt-to-equity ratio of 116.74, a quick ratio of 1.67 and a current ratio of 2.20. The firm has a market capitalization of £747.28 million, a PE ratio of -22.96 and a beta of 1.10.

Oxford Biomedica (LON:OXB) last posted its quarterly earnings results on Thursday, March 26th. The biopharmaceutical company reported GBX (26.92) EPS for the quarter. Oxford Biomedica had a negative net margin of 17.85% and a negative return on equity of 48.56%. On average, equities analysts forecast that Oxford Biomedica will post -31.0799998 earnings per share for the current year.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.